XenaCare Holdings Has Announced That It Will Begin Marketing Its Over-the-Counter (OTC) Pain Reliever, Cobroxin, in Racing One, the Official Annual Publication of NASCAR
DELRAY BEACH, Fla., Oct 22, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an agreement to market its over-the-counter (OTC) pain reliever, Cobroxin, in Racing One, the official annual publication of NASCAR, for the 2010 racing season. Cobroxin is currently available online at Cobroxin.com and will be available soon at various retail outlets. The 2010 Racing One Annual, which will be available starting at the 52nd anniversary of the NASCAR Sprint Cup DAYTONA 500 in February 2010, will be sold through the end of the season. In addition to reaching approximately 8.5 million NASCAR fans attending the 78 NASCAR events being held at the 26 NASCAR sanctioned racetracks, the Publication will also be sold throughout North America in major newsstands, bookstores, grocery stores, retail outlets, train stations, and airports.
"We are excited to be advertising Cobroxin in the 2010 Racing One Annual, as it offers us the opportunity to build awareness around Cobroxin by introducing it through NASCAR, the fastest growing spectator sport in the United States," commented Frank Rizzo, President of XenaCare Holdings. "We look forward to beginning this campaign and continuing to expand our marketing efforts as we introduce Cobroxin through retailers across the United States," he added.
In addition to the Company's agreement to market Cobroxin in NASCAR's Racing One, XenaCare Holdings will also be advertising Cobroxin in the 2009 NFL Alumni Guide and Yearbook. Additionally, the Company announced plans to begin its initial print marketing campaign this fall, which includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced on Monday that it had begun accepting orders for Cobroxin online at Cobroxin.com. The Company intends to announce both online and brick-and-mortar retailers in the coming weeks as they begin offering Cobroxin for sale to consumers.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.xenacareholdings.com/
http://www.cobroxin.com/
For More information contact:
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment